Cancer vaccines

Bibliography

• VONNEGUT K: Timequake. Vintage, London, UK (1998).
   Google Scholar
• BODMER WF, BROWNING MJ, KRAUSA P, et al.: Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY. Acad. Sci. (1993) 690:42–9.
   PubMed Web of Science ®Google Scholar
• DOHRING C, ANGMAN L, SPAGNOLI G, et al.: T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer (1994) 57:754–759.
   PubMed Web of Science ®Google Scholar
• •A useful summary from Lanzavecchia's group.
   Google Scholar
• SOIFFER R, LYNCH T, MIHM M, et al.: Vaccination with irradiated autologous melanoma cells engineered to secret human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Nat. Acad. Sci. (1998) 95 (22) :13141–13146.
   PubMed Web of Science ®Google Scholar
• HOOVER H, BRAND HORST J, PETERS L, et al.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow-up of a Phase III prospectively randomised trial. J. Clin. Oncol. (1993) 11:390.
   PubMed Web of Science ®Google Scholar
• HARRIS J, RYAN L, ADAMS G, et al.: Survival and relapse in adjuvant autologous tumour vaccine therapy for Dukes B and C colon cancer. Proc. Am. Soc. Clin. Oncol. (1994) 13:294.
   Google Scholar
• MORTON D, FOSHAG L, HOON D, et al.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. (1992) 216:463.
   PubMed Web of Science ®Google Scholar
• HART D: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood (1997) 90 (9) :3245–3287.
   PubMed Web of Science ®Google Scholar
• ••A mammoth overview of all that is (or was) known about everyone's favourite APC.
   Google Scholar
• GONG J, DONGSHU C, MASAHIRO K, et al.: Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. (1997) 3(5):558–561.
   PubMed Web of Science ®Google Scholar
• •Persuasive and ground-breaking work from Kufe's laboratory.
   Google Scholar
• GUO Y, WU M, CHEN H, et al.: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science (1994) 263(5146) :518–520.
   PubMed Web of Science ®Google Scholar
• •Apparently now undergoing clinical trials in China.
   Google Scholar
• STUHLER G, WALDEN P: Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes. Cancer Immunol. Immunother. (1994) 39 (5):342–345.
   PubMed Web of Science ®Google Scholar
• ••The basis of a clinical trial in Berlin and also the originators of the cell electrofusion technique.
   Google Scholar
• MAYORDOMO J, ZORINA T, STORKUS W, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. (1995) 1(12) :1297–1302.
   PubMed Web of Science ®Google Scholar
• GJERTSEN MK, BAKKA A, BREIVIK J, et al.: Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet (1995) 346 (8987) 1399–1400.
   PubMed Web of Science ®Google Scholar
• ••A rare piece of therapeutic pragmatism, way ahead of its time.
   Google Scholar
• NESTLE F, ALIJAGIC S, GILLIET M, et al.: Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells. Nature Med. (1998) 4 (3):328–332.
   PubMed Web of Science ®Google Scholar
• BOCZKOWSKI D, NAIR S, SNYDER D, et al.: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. (1996) 184 (2) :465–472.
   Google Scholar
• KWAK LW, CAMPBELL MJ, CZERWINSKI DK, et al.: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New Engl. J. Med. (1992) 327 (17) :1209–1215.
   PubMed Web of Science ®Google Scholar
• •Any results from Ron Levy's team are always worth examining (see also reference [191).
   Google Scholar
• HAWKINS R, ZHU D, OVECKA M, et al.: Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood (1994) 83(11) :3279–3288.
   PubMed Web of Science ®Google Scholar
• HERLYN D, WETTENDORF M, SCHMOLL E, et al.: Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc. Nat. Acad. Sci. (1987) 84:8055–8059.
   PubMed Web of Science ®Google Scholar
• VUIST WM, LEVY R, MALONEY DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bc1-2 protein. Blood (1994) 83(4):899–906.
   PubMed Web of Science ®Google Scholar
• BAUM RP, NIESEN A, HERTEL A, et al.: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer (1994) 73 (Suppl. 3) :1121–1125.
   PubMed Web of Science ®Google Scholar
• •A paper which effectively poses the question, 'Could imaging and therapy be two sides of the same coin?'.
   Google Scholar
• DENTON GW, DURRANT LG, HARD CASTLE JD, et al.: Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int. J. Cancer (1994) 57(1):10–14.
   PubMed Web of Science ®Google Scholar
• DURRANT LG, BUCKLEY TJ, DENTON GW, et al.: Enhanced cell-mediated tumor killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res. (1994) 54(18):4837–4840.
   PubMed Web of Science ®Google Scholar
• MITTELMAN A, CHEN Z, LIU C, et al.: Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse anti-idiotypic monoclonal antibody MK2-23. Cancer Res. (1994) 54:415–421.
   PubMed Web of Science ®Google Scholar
• ROSENBERG S, YANG J, SCHWARTZENTRUBER D, et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Cancer Res. (1998) 4(3):321–327.
   Google Scholar
• TAYLOR-PAPADIMITRIOU J, STEWART L, BURCHELL J, et al.: The polymorphic epithelial mucin as a target for immunotherapy. Ann. NY Acad. Sci. (1993) 690:69–79.
   PubMed Web of Science ®Google Scholar
• ••An excellent summary of the potential immunotherapeutic exploitation of MUC1, from itsdiscoverers.
   Google Scholar
• MILES D, TOWLSON K, GRAHAM R, et al.: A randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer (1996) 74:1292–1296.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON P, WONG G, ADLURI S, et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. (1994) 12(5):1036–1044.
   PubMed Web of Science ®Google Scholar
• •Important for anyone involved in the current Megavax trials.
   Google Scholar
• BORYSIEWICZ L, FIANDER A, NIMAKO M, et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347(9014):1498–1499.
   PubMed Web of Science ®Google Scholar
• •Potentially of great importance in the developing world, where cervical cancer is a big public health issue and access to radiotherapy facilities is often less than adequate.
   Google Scholar